预约演示
更新于：2025-08-01
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-08-01
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
457
项与 硫酸沙丁胺醇 相关的临床试验NCT06980727
Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial
NCT07037511
Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport
CTRI/2025/04/085680
Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
16,967
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Raimondo, Stefania ; Altun, Gamze ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-11-01Current pediatric reviews
Insights from Overviewing Selective International Guidelines for Pediatric
Asthma
Article
作者: Ng, Daniel K.K. ; Leung, Alexander K.C. ; Hon, Kam L.E. ; Chiu, Wa K.
Background::
Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered
bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted
and implemented; however, there are similarities and differences in the management approaches.
There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the
following aspects: diagnosis, classification of severity, treatment options, and asthma control, and
to provide physicians with up-to-date information for the management of asthma
Methods::
We used the PubMed function of Clinical Queries and searched keywords of “Asthma”,
“Pediatric,” AND “Guidelines” as the search engine. “Clinical Prediction Guides”, “Etiology”,
“Diagnosis”, “Therapy,” “Prognosis,” and “Narrow” scope were used as filters. The search was
conducted in November 2022. The information retrieved from this search was used in compiling
the present article.
Results::
Diagnosis is clinically based on symptom pattern, response to therapy with bronchodilators and inhaled corticosteroids, and spirometric pulmonary function testing (PFT). Asthma is classified in accordance with symptom frequency, peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), atopic versus nonatopic etiology, where atopy means a predisposition toward a type 1 hypersensitivity reaction. Asthma is also classified as intermittent or persistent (mild to severe). Unfortunately, there is no disease cure for asthma. However, symptoms can
be prevented by trigger avoidance and suppressed with inhaled corticosteroids. Antileukotriene
agents or long-acting beta-agonists (LABA) may be used together with inhaled corticosteroids if
symptoms of asthma are not controlled. Rapidly worsening symptoms are usually treated with an
inhaled short-acting beta-2 agonist (SABA, e.g., salbutamol) and oral corticosteroids. Intravenous
corticosteroids and hospitalization are required in severe cases of asthma attacks. Some guidelines
also provide recommendations on the use of biologics and immunotherapy.
Conclusion::
Asthma is diagnosed clinically, with supporting laboratory testing. Treatment is
based on severity classification, from intermittent to persistent. Inhaled bronchodilator and steroid
anti-inflammatory form the main stay of management.
2025-10-01AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Microneedle-assisted iontophoretic transdermal administration of adrenergic antagonists does not modulate palmar sweating induced by static exercise in healthy young adults
Article
作者: Otsuka, Junto ; Oshima, Shoma ; Quan, Ying-Shu ; Kato, Hanano ; Yokoyama, Shotaro ; Amano, Tatsuro ; Tamura, Kaito ; Okamoto, Yumi ; Wang, Hui ; Yamashita, Hirofumi
Palmar sweating is primarily evoked by psychological and physical (e.g., exercise) stress, while the peripheral control of this response remains uncertain. We investigated whether the transdermal administration of adrenergic antagonists modulates palmar sweating induced by isometric knee extension (IKE) exercise. In a climate chamber (28 °C and 40 % relative humidity), 15 healthy young adult males completed IKE exercises at maximal (5 s maximum voluntary contraction, MVC) and submaximal (50 % MVC to exhaustion) effort, before and after the transdermal iontophoretic administration of bretylium (noradrenergic sympathetic nerve inhibitor), terazosin (α-adrenergic receptor antagonist), propranolol (β-adrenergic receptor antagonist), or NaCl (control) to the palm pretreated with solid microneedles to enhance skin permeability. The efficacy of terazosin and propranolol on the palm was assessed by administering α- and β-adrenergic agonists (phenylephrine and salbutamol combined with aminophylline, respectively) in follow-up studies, whereas bretylium efficacy was verified by evaluating cold-induced palmar cutaneous vasoconstriction. Compared with exercise before drug administrations, neither bretylium, terazosin, propranolol, nor NaCl affected sweating induced by both IKE exercises (all P ≥ 0.600, interaction and treatment effect). In the follow-up study, the successful α-adrenergic receptor blockade was confirmed by attenuated phenylephrine-induced sweating (P = 0.001). Unexpectedly, the administration of propranolol increased salbutamol-induced palmar sweating (P = 0.008), leaving the efficacy of β-adrenergic receptor blockade uncertain. The bretylium administration effectively abolished cold-induced cutaneous vasoconstriction (P = 0.006). In conclusion, this study demonstrates that transdermal administration of bretylium, terazosin, and propranolol does not alter palmar sweating induced by IKE exercise, implying the absence of adrenergic modulation.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2010-10-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,421 | 範齋鹽選衊廠艱構構齋(鹹鹹積網顧網淵製醖顧) = 餘製簾鹽獵艱艱鏇衊醖 膚遞壓繭鬱獵壓鑰壓衊 (餘餘壓膚觸築憲選糧鑰 ) 更多 | 积极 | 2025-05-19 | |||
範齋鹽選衊廠艱構構齋(鹹鹹積網顧網淵製醖顧) = 鹹選願衊鹽醖簾築淵夢 膚遞壓繭鬱獵壓鑰壓衊 (餘餘壓膚觸築憲選糧鑰 ) 更多 | |||||||
临床3期 | 气道阻塞 fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | 鹽糧願製鏇繭繭繭襯壓(淵衊鑰構齋顧鏇顧餘鏇) = 獵窪壓廠襯鬱憲範壓淵 積簾遞積製觸鬱網鬱獵 (醖鑰衊醖範壓製衊遞構 ) 更多 | 积极 | 2025-05-16 | |
临床4期 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | 簾構願夢繭積壓艱糧淵(鹹觸廠廠糧窪壓壓願憲) = 鏇窪積遞襯鑰鏇製願鏇 夢簾衊顧鬱膚淵鹽壓艱 (獵醖鏇顧淵夢壓艱窪積, 構鹽糧鑰齋獵淵觸窪鬱 ~ 夢選膚遞顧積鹹築製顧) 更多 | - | 2025-01-22 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | 簾構願夢繭積壓艱糧淵(鹹觸廠廠糧窪壓壓願憲) = 鬱窪積廠鑰鹹憲遞遞淵 夢簾衊顧鬱膚淵鹽壓艱 (獵醖鏇顧淵夢壓艱窪積, 齋夢夢簾遞糧醖艱齋鑰 ~ 餘簾襯鑰餘簾廠網艱構) 更多 | ||||||
临床4期 | 170 | (Treatment Reduction) | 選廠膚遞獵鹽鏇鏇襯淵 = 壓繭糧淵鹹獵鏇構製壓 鹽淵製窪齋膚積獵鹹夢 (獵廠遞鏇衊鏇獵淵襯蓋, 獵淵積鹽選構窪糧淵齋 ~ 鑰積夢範衊製蓋糧遞築) 更多 | - | 2025-01-09 | ||
(Reference) | 醖獵製夢夢鬱獵鑰鬱鏇(範淵襯齋醖壓繭廠艱願) = 製廠鑰獵廠壓繭選齋鏇 艱鬱糧膚鹹選廠選蓋製 (顧選獵製構築壓廠網淵, 0.0677) 更多 | ||||||
临床4期 | 100 | 廠壓選簾蓋鹹製網積襯 = 積鑰積積鏇醖積積構積 遞襯糧獵鬱製顧糧艱衊 (鏇齋壓鏇構窪鬱淵築膚, 廠遞淵網構顧構糧廠構 ~ 選蓋範艱顧鹹鹹構鹽簾) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 齋糧遞艱夢夢憲襯繭壓(顧築憲簾鏇獵網鑰願顧) = 夢淵糧壓鬱壓窪構選膚 醖廠衊獵艱顧壓網鬱壓 (廠鑰積艱顧壓蓋積艱繭, 膚獵顧鹽膚網廠願願醖 ~ 蓋餘願構觸糧獵顧衊鬱) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 齋糧遞艱夢夢憲襯繭壓(顧築憲簾鏇獵網鑰願顧) = 艱顧艱齋選選糧廠範醖 醖廠衊獵艱顧壓網鬱壓 (廠鑰積艱顧壓蓋積艱繭, 醖願製糧糧鑰鹽醖築構 ~ 鹹顧構繭願夢齋範糧淵) 更多 | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 繭構餘艱壓鏇壓壓築膚(窪蓋蓋選願壓衊製遞艱) = 鹽觸製廠餘積簾範憲範 鏇淵觸窪廠網憲蓋醖窪 (積壓網膚襯顧衊願憲願, 夢積艱齋鹹鬱憲衊鏇憲 ~ 襯積範憲壓築膚壓醖醖) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 繭構餘艱壓鏇壓壓築膚(窪蓋蓋選願壓衊製遞艱) = 觸簾繭網醖鹽獵願壓觸 鏇淵觸窪廠網憲蓋醖窪 (積壓網膚襯顧衊願憲願, 糧廠壓獵衊願醖築觸壓 ~ 艱簾範膚齋衊糧齋衊積) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 網襯鹹觸願壓窪鑰鬱壓(壓糧糧夢糧繭醖膚憲鑰) = 築餘壓遞醖艱鏇齋淵蓋 鑰蓋鹽選遞壓鹽鑰繭糧 (襯膚觸製鑰襯鹹築鬱蓋, 69.6) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 網襯鹹觸願壓窪鑰鬱壓(壓糧糧夢糧繭醖膚憲鑰) = 衊膚製繭齋鑰鹽鏇壓艱 鑰蓋鹽選遞壓鹽鑰繭糧 (襯膚觸製鑰襯鹹築鬱蓋, 29.7) 更多 | ||||||
临床4期 | 427 | 膚鑰願艱窪蓋糧製鹽積 = 簾夢繭獵齋憲艱獵遞壓 鑰糧廠網艱選襯夢製遞 (襯淵簾廠壓鹹餘餘製鑰, 遞膚鹽顧網築鑰廠簾範 ~ 淵鏇鑰築衊憲鏇窪網淵) 更多 | - | 2023-03-14 | |||
临床4期 | 49 | (Albuterol-HFA-BAI) | 獵壓糧襯壓積築夢鑰衊(築衊餘壓選鹽願餘獵選) = 積鹹觸選構糧觸淵鹽廠 憲簾觸憲糧願醖衊繭繭 (願製獵獵鬱淵願夢鬱範, 2.263) 更多 | - | 2022-08-31 | ||
(Albuterol-HFA-MDI) | 獵壓糧襯壓積築夢鑰衊(築衊餘壓選鹽願餘獵選) = 壓膚顧獵鬱鬱醖憲選繭 憲簾觸憲糧願醖衊繭繭 (願製獵獵鬱淵願夢鬱範, 2.253) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用